$5.15-0.16 (-3.01%)
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
Cybin D/B/A Helus Pharma in the Healthcare sector is trading at $5.15. The stock is currently near its 52-week low of $4.29, remaining 20.3% below its 200-day moving average. Technical signals show neutral RSI of 46 and bearish MACD signal, explaining why HELP maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in pha...
Earlier this month, Helus Pharma (operating as Cybin) reshaped its leadership by appointing interim CEO Eric So, expanding medical leadership with Dr. Ken Kramer as Senior Vice President of Medical Affairs, and adding renowned experts Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board. By bringing together high-profile figures in biotechnology, CNS drug development, and medical affairs, Helus Pharma is signaling an emphasis on clinically rigorous development of its...
Shares of some psychedelic drug companies gained Friday morning after the US Food and Drug Administr
AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.
Compass Pathways (CMPS) and other psychedelic shares were up in Monday premarket activity, after US
Looking at Cybin Inc.'s ( NASDAQ:HELP ) insider transactions over the last year, we can see that insiders were net...